Kite's Tecartus (brexucabtagene autoleucel) authorised by Health Canada for the treatment of relapsed or refractory mantle cell lymphoma

Gilead

28 October 2021 - Tecartus is first CAR T therapy in mantle cell lymphoma and Kite becomes the first company with multiple authorised cell therapies in Canada.

Gilead Sciences Canada has received a Health Canada Notice of Compliance for Tecartus (brexucabtagene autoleucel). 

Tecartus is a chimeric antigen receptor T-cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy including a Bruton's tyrosine kinase inhibitor.

Read Gilead press release

Michael Wonder

Posted by:

Michael Wonder